Home General Information Accommodations and Travel Agenda Abstracts Sponsorships Patient Symposium
Fifteenth International Vasculitis & ANCA Workshop.
May 15-18, 2011 in Chapel Hill, North Carolina.
The program is designed for clinicians and scientists who are interested in progressing research and clinical trials into ANCA associated vasculitis.
The University of North Carolina at Chapel Hill
University of North Carolina Kidney Center
UNC

Get Adobe Flash player



Scientific Program

Click here to download the meeting program

Sunday, May 15th
4:00-8:00 Registration

6:30-7:30

 

7:30-8:30

Keynote Address: Fokko van der Woude
Lecture: Where are we in Understanding the Pathogenetic Role of ANCA in Small Vessel Vasculitis?

Welcome Reception

Cees Kallenberg, MD, PhD

Monday, May 16th
7:30-8:00 Continental Breakfast
8:00-8:15 Introduction and Welcome
8:15-9:30 SESSION 1: Nomenclature and Classification of Vasculitis
Moderators: Wolfgang Gross, MD & Eric Matteson, MD
8:15-8:35 Overview of Nomenclature and Classification of Vasculitis J. Charles Jennette, MD
8:35-8:55 Update on ACR/EULAR Classifications & Diagnostic Criteria Raashid Luqmani, MD
8:55-9:15 Pathologic Classification of ANCA GN Ingeborg Bajema, MD, PhD
9:15-9:30 Open Discussion
9:30-10:30 SESSION 2: Origins of Autoimmunity
Moderators: Cees Kallenberg, MD, PhD & Charles Pusey, DSc, FRCP
9:30-10:10 Autoantigen Conformopathy Billy Hudson, PhD
10:10-10:30 Epigenetics and Complementary Proteins Ronald J. Falk, MD
10:30-11:00 SESSION 3: Status of European GWAS                                                                           Kenneth Smith, PhD
11:00-12:00 POSTER SESSION 1
  • Genetic Influences & Antibody Specificity
  • Epidemiology & Diagnostics
  • Serologies & Biomarkers
12:00-1:45 Lunch Break
1:45-3:00 SESSION 4A: Serology in the Classification and Management of Vasculitis
Moderators: Franco Ferrario, MD & Judy A. Savige, MD, PhD
1:45-2:05 Optimum Approaches to Clinical ANCA Testing Elena Csernok, PhD
2:05-3:00 Abstract Presentations
  • Mahler, Michael: PR3-ANCA in Inflammatory Bowel Disease is Restricted to Ulcerative Colitis and Associated with P-ANCA Staining Pattern
  • Mahr, Alfred: Cluster Analysis and Clinical Phenotypes of ANCA-Associated Vasculitis
  • McAdoo, Stephen: PR3-ANCA Positivity in Patients Without Primary ANCA-Associated Vasculitis
  • Berden, Annelies: Anti-Plasminogen Antibodies in Patients with ANCA-Associated Vasculitis Compromise Fibrinolysis and are Related to Hallmark Histopathological Renal Lesions
  • Guilpain, Philippe: Association Between the Sialylation Level of Anti-Proteinase 3 (PR3) Antibodies and the Activity of Wegener’s Granulomatosis
1:45-3:00 SESSION 4B: Membrane Antigen Biology
Moderators: Jorgen Wieslander, MD, PhD & Jan-Willem Cohen-Tervaert, MD, PhD
1:45-2:00 The Role of Membrane Antigens in ANCA Disease: The Berlin Perspective Ralph Kettritz, MD
2:00-2:15 The Role of Membrane Antigens in ANCA Disease: The Lund Perspective Thomas Hellmark, PhD
2:15-2:30 The Role of Autoantigen Protein Partners in ANCA Disease Véronique Witko-Sarsat, PhD
2:30-3:00 Open Discussion
3:00-4:00 POSTER SESSION 2
  • B & T Cell Immunology
  • Clinical Phenotypes
  • Quality of Life
4:00-4:30 Refreshment Break
4:30-6:00 SESSION 5A Global Epidemiology of Vasculitis
Moderators: Susan L. Hogan, PhD, MPH & Sofia Lionaki, MD
4:30-4:50 ANCA Disease in Asia Ming-Hui Zhao, MD, PhD
4:50-6:00 Abstract Presentations
  • Makino, Hirofumi: Observational Cohort Study of Remission Induction Therapy in Japanese Patients with ANCA-associated Vasculitides (RemIT-JAV); Preliminary report
  • Hruskova, Zdenka: ANCA-Associated Vasculitides in the Czech Population - Data from the National Registry
  • Schmidt, Jean: Takayasu Arteritis: Diagnostic features, and Treatment: An American Cohort of 126 Patients
  • Watts, Richard: Contrasting Epidemiology of Wegener's Granulomatosis and Microscopic Polyangitis
  • Direskeneli, Haner: Takayasu's Arteritis is Associated with HLA-B*52, but not with B*51 in Turkey
  • Pradhan, Vandana: ANCA Serology in Indian AAV patients: A Study of 285 Patients from Mumbai, Western India
  • Flores-Suarez, Luis Felipe: Giant Cell Arteritis (GCA) in Mexicans
4:30-6:00 SESSION 5B: B-Cells and T-Cells in Autoimmunity
Moderators: Donna Bunch, PhD & Peter Hewins, MD, PhD
4:30-4:45 T Cells in the Induction of Human Autoimmune Vasculitis Peter Lamprecht, MD
4:45-5:00 B-Cells in the Induction of Human Autoimmune Vasculitis Alan Salama, MD
5:00-6:00 Abstract Presentations
  • Chen, Nan: Computer Aided Drug Design of A Potential And Selective Small Peptide Inhibiting Interaction of FcγIIa and ANCA
  • Morgan, Matthew: Expansion of CD4+ CD28- T Cells in Wegener's Granulomatosis is Driven by CMV and Associated with an Increased Risk of Mortality and Infection
  • Holden, Neil: ANCA Stimulated Neutrophils Release BLyS and Promote B Cell Survival in vitro
  • Holle, Julie: Serum cf-DNA/NETs are Elevated in AAV and Induce Maturation of DC-like Monocytes in vitro
  • Free, Meghan: Patients with ANCA Disease have Altered T Cell Subsets and FoxP3 Protein in the Periphery
  • Kitching, Richard: An Immunodominant T Cell epitope of Myeloperoxidase can Induce Cell-mediated Injury in Anti-MPO Glomerulonephritis

Tuesday, May 17th
7:30-8:00 Continental Breakfast
8:00-9:30 SESSION 6: Pathogenesis of Vasculitis
Moderators: Jan-Willem Cohen-Tervaert, MD, PhD & Kazuo Suzuki, PhD
8:00-8:20 Pathogenesis of Giant Cell Arteritis Cornelia Weyand, MD, PhD
8:20-8:40 Pathogenesis of Kawasaki Disease Kei Takahashi, MD
8:40-9:00 Pathogenesis of ANCA Caroline Savage, MD, PhD
9:00-9:20 Translation of Pathogenic Understanding to Novel Therapies Patrick N. Nachman, MD
9:20-9:30 Abstract Presentation
  • Little, Mark: Human Anti-PR3 ANCA Recapitulate Systemic Vasculitis in Mice with a Humanised Immune System
9:30-11:00 SESSION 7: Induction Therapy in ANCA Vasculitis
Moderators: Patrick N. Nachman, MD & Luis Felipe Flores-Suarez, MD, PhD
9:30-9:50 Rituximab in Induction Therapy for ANCA Vasculitis John Niles, MD
9:50-10:10 Cyclophosphamide in Induction Therapy for ANCA Vasculitis Carol Langford, MD
10:10-11:00 Abstract Presentations
  • Berden, Annelies: Long Term Renal Outcome of Patients Enrolled in the CYCAZAREM Trial
  • Casian, Alina: Plasma Exchange for Severe Renal Vasculitis: Long-Term Follow-up of the MEPEX Trial
  • Harper, Lorraine: Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitis: A European Multicenter Randomised Controlled Trial - Long Term Follow-up
  • Jones, Rachel: Two Year Follow-up Results from a Randomised Trial of Rituximab Versus Cyclophosphamide for ANCA-Associated Renal Vasculitis: RITUXVAS
  • Specks, Ulrich: Long-term Efficacy and Safety Results of RAVE-trial
11:00-12:00 Poster Session 3
  • Pathogenesis I
  • Treatment & Management
  • Treatment & Management
12:00-1:45 Lunch Break
1:45-3:00 SESSION 8A: Predictive, Diagnostic and Prognostic Biomarkers of Vasculitis - Part 1
Moderators: Alfred Mahr, MD and Mary Anne Dooley, MD, MPH
1:45-2:05 Diagnostic Markers of Nervous System Vasculitis Leonard H. Calabrese, DO
2:05-2:25 Diagnostic Markers of Giant Cell Arteritis Loic Guillevin, MD
2:25-3:00 Abstract Presentations
  • Tezuka, Daisuke: High Standardized Uptake Value of 18F-Fluorodeoxyglucose-positron Emission Tomography/Computer Tomography is Correlated with Disease Activity in Patients with Takayasu Arteritis
  • Grayson, Peter: Distribution of Thoracic Large Arterial Lesions in Takayasu’s Arteritis Compared to Giant Cell Arteritis
1:45-3:00 SESSION 8B: Genetics
Moderators: Jiajin Yang, MD & Lorraine Harper, MD
1:45-3:00 Abstract Presentations
  • Yang, Jiajin: DRB*1*15 Allele is a Risk Factor for PR3-ANCA Disease in African Americans
  • Harper, Lorraine: ANCA-associated Vasculitis, Polymers and Carriage of the Z allele of 1-antitrypsin
  • Kimberly, Robert: IgA and IgG ANCAs Modulate Disease Severity in a Genetically Dependent Fashion
  • Ciavatta, Dominic: Modifier Loci for Anti-MPO Model of ANCA Disease Revealed by Mouse Comparative Genomics
  • Hu, Nan: Differential Expression of Granulopoiesis Related Genes in Neutrophil Subsets Distinguished by Membrane Expression of CD177, the Receptor of the Autoantigen Proteinase 3 in Wegener's Granulomatosis
3:00-4:00 Poster Session 4
  • Pathogenesis II
  • Informative case reports
  • Other clinical research
4:00-4:30 Refreshment Break
4:30-6:00 SESSION 9A : Predictive, Diagnostic and Prognostic Biomarkers of Vasculitis - Part 2
Moderators: David Henke and Brent Senior, MD
4:30-4:45 Diagnostic Markers of Upper Respiratory Tract Vasculitis Niels Rasmussen, MD
4:45-5:00 Diagnostic Markers of Lung Vasculitis Ulrich Specks, MD
5:00-5:15 Diagnostic Markers of Churg-strauss: ANCA Positive Versus ANCA Negative Christian Pagnoux, MD, PhD Christian Pagnoux, MD, PhD
5:15-6:00 Abstract Presentations
  • Guillevin, Loic: Churg-Strauss Syndrome (CSS) Phenotypes: Are Magneitc Resonance Imaging (MRI)-detected Cardiac Anomalies Associated with ANCA-negativity?
  • Szczeklik, Wojciech: 12-HETE as a Biomarker in Exhaled Breath Condensates, Distinguishes Churg-Strauss Syndrome from Hypereosinophilic Syndrome, Asthma and Healthy Controls
  • Jakiela, Bogdan, J: Th2-type Immune Response Dominates in the Airways of Churg-Strauss Syndrome Patients
4:30-6:00 SESSION 9B: Animal Models
Moderators: Hong Xiao, MD & Mark Little, MD, PhD
4:30-4:50 Animal Models of ANCA-AAV: An Overview Peter Herringa, PhD
4:50-5:10 The Collaborative Cross: A Community Resource for Biomedical Research Fernando Pardo Manuel de Villena
5:10-6:00 Abstract Presentations
  • Oharaseki, Toshiaki: Anti TNF-α Therapy for Murine Systemic Vasculitis Induced by Candida Albicans Water-soluble Fraction: An Animal Model of Kawasaki Disease
  • Schreiber, Adrian: Dipeptidyl Peptidase I-dependent IL-1-release Mediates ANCA-induced Nephritis
  • Xiao, Hong: C5a Engagement of C5a Receptors but not C6 is Required for Induction of Glomerulonephritis (GN) by Anti-MPO IgG
  • Ishizu, Akihiro: A Model of Vasculitis Induced by Autoreactive T cells Against Vasular Endothelial Cells
  • Holdsworth, Stephen: Aberrant Presentation of MPO Induces Tolerance and Protects from Experimental Anti-MPO Glomerulonephritis

Wednesday, May 18th
7:30-8:00 Continental Breakfast
8:00-9:00 SESSION 10: The Lamp2 Controversy
Moderators: Lorraine Harper, MD & Thomas Hellmark, PhD
8:00-8:20 Autoantibodies to hLAMP-2 Renate Kain, MD
8:20-8:40 Is LAMP-2 a Target of ANCA? Gloria Preston, PhD
8:40-9:00 Open Discussion
9:00-10:30 SESSION 11: Clinical Studies: Present and Future
Moderators: Maria Cid, MD & Melanie S. Joy, PharmD, PhD
9:00-9:15 Update on the Activities of the Vasculitis Clinical Research Consortium Peter Merkel, MD, MPH
9:15-9:30 Rituximab Trials David Jayne, MD
9:30-9:45 Clinical Trials Update: Studies from the European Vasculitis Study Group Kirsten de Groot, MD, PhD
9:45-10:30 Abstract Presentations
  • McGregor, JulieAnne: Glucocorticoid Use Beyond 6 Months Does Not Prevent Relapses But Increases Risk of Infection
  • Walsh, Michael: PEXIVAS: Design of a Randomised Controlled Trial of Plasma Exchange and Gluocorticoid Dosing in ANCA Associated Vasculitis
  • Pagnoux, Christian: Are Patients with ANCA-associated Vasculitis Entered in Clinical Trials Representative of Patients Followed in Observational Cohorts?
  • Smith, Rona: Proposal for a Randomised Controlled Trial Comparing Rituximab to Standard Immunosuppression as Maintenance Therapy in ANCA Associated Vasculitis
10:30-11:30 SESSION 12: Endothelium and Microparticles
Moderators: Vladimir Tesar, MD, PhD & Alan Salama, MD
10:30-10:50 Neutrophil/ Endothelium Cross-Activation in Presence of ANCA Philip LeSavre, MD
10:50-11:10 Microparticles in ANCA Vasculitis Marion Haubitz, MD
11:10-11:30 Abstract Presentations
  • Eleftheriou, Despina: Endothelial Injury and Repair in Childhood Primary Angiitis of the Central Nervous System
  • Hong, Ying: ANCA Induced Neutrophil Microparticles in the Pathogenesis of ANCA Associated Vasculitis
11:30-1:00 Lunch Break
1:00-2:00 SESSION 13: Neutrophil Activation in Vasculitis
Moderator: Kerstin Westman, MD, PhD
1:00-1:20 Natural ANCA Antibodies Marten Segelmark, MD
1:20-2:00 Abstract Presentations
  • Pepper, Ruth: Critical Role for Calprotectin in ANCA Associated Vasculitis and Glomerulonephritis
  • McLeish, Kenneth: Mechanisms of Cytokine Priming of Human Neutrophils
  • Tadema, Henko: Leukocyte Toll-like Receptor Expression in ANCA-associated Vasculitis: Differential Expression by Monocytes and Natural Killer Cells
  • Halbwachs-Mecarelli, Lise: Neutrophils and complement activate eachothers. An inflammation amplification loop further enhanced by ANCA.
2:00-3:00 SESSION 14: Clinical Vasculitis Phenotypes, Risk Factors and Outcomes
Moderators: Gina Gregorini, MD & Joanne M. Jordan, MD, MPH
2:00-3:00 Abstract Presentations
  • Tomasson, Gunnar: Measurement of Health-Related Quality of Life Among Patients with ANCA-Associated Vasculitis Using the SF-36
  • McGrath, Martina: Contaminated Cocaine and ANCA Associated Vasculitis
  • Tuin, Janneke: Pregnancy in Women with Wegener’s Granulomatosis: Outcome for Mother and Child
  • Hajj-Ali, Rula: The Relationship Between Inflammatory Disease in Wegener's Granulomatosis with the Development of Subclinical Atherosclerosis
  • Hernandez-Rodriguez, Jose: Testicular Vasculitis: Findings Differentiating Isolated from Systemic Disease in 72 Patients
  • Chen, Nan: Renal Involvement in PTU Associated ANCA Positive Vasculitis and Primary ANCA Associated Vasculitis
3:00-4:00 SESSION 15: Looking Ahead and Passing The Baton
3:00-3:30 What Does the Future Hold for Clinical Studies in Vasculitis? Gary Hoffman, MD, MS
3:30-4:00 What Does the Future Hold for Basic Science Studies in Vasculitis? Ronald J. Falk, MD
Thurston Arthritis Research Center
© 2011 anca2011.org.